

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under The Securities Exchange Act of 1934
(Amendment No. 15)*

Aptose Biosciences Inc. (formerly Lorus Therapeutics Inc.)

(Name of Issuer)

Common Stock

(Title of Class of Securities)

03835T101 (formerly 544192107)

(CUSIP Number)

Herbert Abramson
22 St. Clair Avenue East, 18th Floor
Toronto, Ontario, Canada
M4T 2S3
(416) 361-1498

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

May 21, 2015

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON Technifund Inc. I.R.S. Identification No. -- Not Applicable	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3	SEC Use Only	
4	SOURCE OF FUNDS WC	
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) <input type="checkbox"/>	
6	CITIZENSHIP OR PLACE OF ORGANIZATION Ontario, Canada	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 61,811
	8	SHARED VOTING POWER 0
	9	SOLE DISPOSITIVE POWER 61,811
	10	SHARED DISPOSITIVE POWER 0
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 61,811 *	
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES <input type="checkbox"/>	
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0.5% *	
14	TYPE OF REPORTING PERSON HC	

*See Item 5

1	NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON Herbert Abramson I.R.S. Identification No. -- Not Applicable	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3	SEC Use Only	
4	SOURCE OF FUNDS PF	
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) <input type="checkbox"/>	
6	CITIZENSHIP OR PLACE OF ORGANIZATION Canadian	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 590,554
	8	SHARED VOTING POWER 0
	9	SOLE DISPOSITIVE POWER 590,554
	10	SHARED DISPOSITIVE POWER 0
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 590,554 *	
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES <input type="checkbox"/>	
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 4.98% *	
14	TYPE OF REPORTING PERSON IN	

*See Item 5

This Amendment No. 15 (the “Amendment”) with respect to the Common Stock of Aptose Biosciences Inc. (formerly Lorus Therapeutics Inc.) (the “Issuer”) amends and supplements the Schedule 13D, as amended (the “Schedule 13D”), which was originally filed on July 23, 2007. Capitalized terms used herein but not defined shall have the meanings ascribed thereto in the Schedule 13D. The Schedule 13D is hereby amended and supplemented as follows:

Item 3. Source and Amount of Funds or Other Consideration

The net purchase price of the Common Stock reported in this Schedule 13D was CDN\$7,362,745.16. The Common Stock to which this Schedule 13D relates was purchased using working capital, in respect of shares purchased by Technifund, and personal funds in respect of shares purchased by Abramson.

Item 5. Interest in Securities of the Issuer

(a) As of the close of business on May 21, 2015, the Reporting Persons’ beneficial ownership of Common Stock was 590,554 shares, which represents approximately 4.98% of the outstanding shares of the Issuer. Of this amount, 528,743 shares of Common Stock were held by Abramson directly and 61,811 shares of Common Stock were held by Technifund.

(b) The responses of the Reporting Persons to Items 7 through 13 on the cover pages are incorporated herein by reference. All responses reflect the beneficial ownership as of the close of business on May 21, 2015. Abramson exercises sole voting and dispositive power over shares held by him and Technifund. Technifund exercises sole voting and dispositive power over the shares held by it.

(c) The following are all transactions in the Common Stock beneficially owned by the Reporting Persons that were effected during the sixty days prior to May 21, 2015:

Abramson directly effected the following purchases/sales through open market transactions:

Date of Transaction	Quantity Purchased (Sold)	Price/Share	Currency
3/25/2015	(5,573)	5.6491	USD
3/26/2015	(900)	6.6589	CAD
3/26/2015	(3,210)	5.3812	USD
3/27/2015	(13,600)	5.4203	USD
4/2/2015	(10,000)	5.4999	USD
5/21/2015	(1,000)	7.5800	CAD
5/21/2015	(3,000)	6.3099	USD

(d) Other than the Reporting Persons, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock reported in this Schedule 13D.

(e) After giving effect to the transactions described in subsection “(c)” above, the Reporting Persons ceased to be the beneficial owners of more than five percent of the Issuer’s Common Stock. This is the final amendment to this Schedule 13D and an exit filing for the Reporting Persons.

Item 7. Material to be Filed as Exhibits

Exhibit B Joint Filing Agreement, dated July 31, 2007, by and between Abramson and Technifund*

* Previously filed with the Schedule 13D on July 23, 2007.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated October 8, 2015

/s/ Herbert Abramson
Herbert Abramson

TECHNIFUND INC.

By: /s/ Herbert Abramson
Name: Herbert Abramson
Title: President
